Dataset Viewer
Auto-converted to Parquet
id
string
patient
dict
question
dict
answer_expected
string
answer_explanation
string
difficulty_rationale
string
sources
list
citations
list
otherSource
null
AITX-00001
{ "clinical_context": "Progressive muscle weakness", "genotype": [ { "gene": "DMD", "transcript": "NM_004006.2", "variant_cdna": "c.7544_9286del", "variant_protein": "p.(Thr2516_Ala3096del)", "zygosity": "hemizygous" } ] }
{ "answer_format": "multiple_choice", "category": "Established_Targeted", "date_submitted": "2025-08-01", "prompt": "To which of the following targeted therapies would this variant be most likely amenable: Golodirsen, Viltolarsen, Eteplirsen, Casimersen, Ataluren, or None?" }
Eteplirsen
Variant results in deletion of exons 52-63, which is listed as amenable to exon 51 skipping
[ "GeneReviews", "PubMed/Literature" ]
[]
null
AITX-00002
{ "clinical_context": "Progressive muscle weakness", "genotype": [ { "gene": "DMD", "transcript": "NM_004006.2", "variant_cdna": "c.10453_10454delinsTA", "variant_protein": "p.(Leu3485Ter)", "zygosity": "hemizygous" } ] }
{ "answer_format": "multiple_choice", "category": "Established_Targeted", "date_submitted": "2025-08-01", "prompt": "To which of the following targeted therapies would this variant be most likely amenable: Golodirsen, Viltolarsen, Eteplirsen, Casimersen, Ataluren, or None?" }
Ataluren
Variant results in a nonsense in exon 74, which is amenable to nonsense readthrough
[]
[]
null
AITX-00003
{ "clinical_context": "Progressive muscle weakness", "genotype": [ { "gene": "DMD", "transcript": "NM_004006.2", "variant_cdna": "c.70T>C", "variant_protein": "p.(Trp24Arg)", "zygosity": "hemizygous" } ] }
{ "answer_format": "multiple_choice", "category": "Established_Targeted", "date_submitted": "2025-08-01", "prompt": "To which of the following targeted therapies would this variant be most likely amenable: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Ataluren, or None?" }
None
Results in a missense in exon 2, which is not amenable to nonsense readthrough and is upstream from skippable exons
[]
[]
null
AITX-00004
{ "clinical_context": "Recurrent nephrocalcinosis and chronic kidney disease", "genotype": [ { "gene": "AGXT", "transcript": "NM_000030.3", "variant_cdna": "c.508G>A", "variant_protein": "p.(Gly170Arg)", "zygosity": "homozygous" } ] }
{ "answer_format": "string_match", "category": "Established_Targeted", "date_submitted": "2025-08-01", "prompt": "What targeted, small molecule therapy is available for this patient? Provide the generic name or None." }
Pyridoxine
Missense variants are amenable to pyridoxine treatment
[ "GeneReviews" ]
[ "https://www.ncbi.nlm.nih.gov/books/NBK1283/" ]
null
AITX-00005
{ "clinical_context": "Recurrent nephrocalcinosis and chronic kidney disease", "genotype": [ { "gene": "AGXT", "transcript": "NM_000030.3", "variant_cdna": "c.33dup", "variant_protein": "p.(Lys12GlnfsTer156)", "zygosity": "homozygous" } ] }
{ "answer_format": "binary", "category": "Established_Targeted", "date_submitted": "2025-08-01", "prompt": "Is this patient predicted to be responsive to pyridoxine? Answer yes or no." }
No
Pyridoxine is not effective for patients with null variants
[ "GeneReviews" ]
[ "https://www.ncbi.nlm.nih.gov/books/NBK1283/" ]
null
AITX-00006
{ "clinical_context": "7 year old with recurrent nephrocalcinosis and chronic kidney disease", "genotype": [ { "gene": "AGXT", "transcript": "NM_000030.3", "variant_cdna": "c.33dup", "variant_protein": "p.(Lys12GlnfsTer156)", "zygosity": "homozygous" } ] }
{ "answer_format": "string_match", "category": "Established_Targeted", "date_submitted": "2025-08-01", "prompt": "What targeted, genetic therapies are approved for this patient in the US? Provide the generic name." }
Lumasiran
Lumasiran is approved for patients of all ages whereas Nedosiran is only approved for patients age >9.
slight change in patient age changes the answer
[ "GeneReviews" ]
[ "https://www.ncbi.nlm.nih.gov/books/NBK1283/" ]
null
AITX-00007
{ "clinical_context": "Global developmental delay", "genotype": [ { "gene": "DDC", "transcript": "NM_001082971.2", "variant_cdna": "c.286G>A", "variant_protein": "p.(Gly96Arg)", "zygosity": "homozygous" } ] }
{ "answer_format": "string_match", "category": "Established_Targeted", "date_submitted": "2025-08-01", "prompt": "What is the youngest age for which a gene therapy is approved for this patient's genetic condition in the united kingdom? Answer with the format \"X months\"." }
18 months
specified on GeneReviews
[ "GeneReviews" ]
[ "https://www.ncbi.nlm.nih.gov/books/NBK595821/" ]
null
AITX-00008
{ "clinical_context": "joint hypermobility, skin hyperextensibility, and easy bruising", "genotype": [ { "gene": "COL1A1", "transcript": "NM_000088.4", "variant_cdna": "c.1678G>A", "variant_protein": "p.(Gly560Ser)", "zygosity": "heterozygous" } ] }
{ "answer_format": "string_match", "category": "Established_Supportive", "date_submitted": "2025-08-01", "prompt": "What two medications are most established for decreasing bruising? List generic names in alphabetical order" }
ascorbic acid, desmopressin
specified in management on GeneReviews
[ "GeneReviews" ]
[ "https://www.ncbi.nlm.nih.gov/books/NBK1244/#eds.Management" ]
null
AITX-00009
{ "clinical_context": "Patient with SLC35A2-CDG who is experiencing seizures and global developmental delay", "genotype": [ { "gene": "SLC35A2", "transcript": "NM_005660.3", "variant_cdna": "c.3G>A", "variant_protein": "p.Met1Ile", "zygosity": "heterozygous" } ] }
{ "answer_format": "string_match", "category": "Clinical_Trials", "date_submitted": "2025-08-01", "prompt": "What clinical trial developing a new therapeutic for this condition is recruiting or listed as upcoming/not yet recruiting? Return a clinical trials ID" }
NCT05402384
search for SLC35A2 on ClinicalTrials.gov returns only 2 trials, 1 of which is upcoming
[ "ClinicalTrials.gov" ]
[ "https://clinicaltrials.gov/study/NCT05402384" ]
null
AITX-00010
{ "clinical_context": "seizures and global developmental delay. Age 2 months, Hemoglobin 5, Normal liver labs, Not enrolled in other trials", "genotype": [ { "gene": "SLC35A2", "transcript": "NM_005660.3", "variant_cdna": "c.3G>A", "variant_protein": "p.Met1Ile", "zygosity": "heterozygous" } ] }
{ "answer_format": "binary", "category": "Clinical_Trials", "date_submitted": "2025-08-01", "prompt": "Is this patient eligible for clinical trial NCT05402384? Answer yes or no." }
No
Exclusion criteria lists hemoglobin <7
[ "ClinicalTrials.gov" ]
[ "https://clinicaltrials.gov/study/NCT05402384" ]
null
AITX-00011
{ "clinical_context": "early-onset seizures and developmental delays", "genotype": [ { "gene": "KCNT1", "transcript": "NM_020822.3", "variant_cdna": "c.2849G>A", "variant_protein": "p.Arg950Gln", "zygosity": "heterozygous" } ] }
{ "answer_format": "string_match", "category": "Clinical_Trials", "date_submitted": "2025-08-01", "prompt": "For which clinical trials evaluating new therapeutics is this patient eligible? Provide a clinical trial ID or answer None." }
None
Only a natural history study is listed.
[ "ClinicalTrials.gov" ]
[ "https://clinicaltrials.gov/search?cond=KCNT1" ]
null
AITX-00012
{ "clinical_context": "intellectual disability, seizures, and developmental delays", "genotype": [ { "gene": "GRIN2B", "transcript": "NM_000834.5", "variant_cdna": "c.2755C>T", "variant_protein": "p.Gln919Ter", "zygosity": "heterozygous" } ] }
{ "answer_format": "multiple_choice", "category": "Drug_Development_and_Repurposing", "date_submitted": "2025-08-01", "prompt": "Is it more likely amenable to treatment with Memantine, L-serine, or Radiprodil" }
L-Serine
Variant is a LOF variant. L-serine is being used for LOF variants whereas the others are being used for GOF variants
[ "PubMed/Literature" ]
[ "https://academic.oup.com/brain/article/147/5/1653/7611854?login=false" ]
null
AITX-00013
{ "clinical_context": "progressive cerebellar ataxia and peripheral neuropathy", "genotype": [ { "gene": "ANO10", "transcript": "NM_018075.5", "variant_cdna": "c.289del", "variant_protein": "p.(Met97Ter)", "zygosity": "homozygous" } ] }
{ "answer_format": "numeric_match", "category": "Variant_Assessment", "date_submitted": "2025-08-01", "prompt": "How many amino acids are coded for by the exon in which this variant occurs? Answer with a number" }
66
visual inspection on Ensembl
[ "Other" ]
[]
null
AITX-00014
{ "clinical_context": "progressive cerebellar ataxia and peripheral neuropathy", "genotype": [ { "gene": "ANO10", "transcript": "NM_018075.5", "variant_cdna": "c.289del", "variant_protein": "p.(Met97Ter)", "zygosity": "homozygous" } ] }
{ "answer_format": "numeric_match", "category": "Variant_Assessment", "date_submitted": "2025-08-01", "prompt": "What percentage of the total coding transcript for this gene are encoded by the exon in which this variant occurs? Answer with a decimal to nearest tenth." }
0.1
66/660 = 0.1
[ "Other" ]
[]
null
AITX-00015
{ "clinical_context": "childhood-onset generalized dystonia", "genotype": [ { "gene": "KMT2B", "transcript": "NM_014727.3", "variant_cdna": "c.8079delC", "variant_protein": "p.(Ile2694SerfsTer44)", "zygosity": "heterozygous" } ] }
{ "answer_format": "binary", "category": "Variant_Assessment", "date_submitted": "2025-08-01", "prompt": "Based on typical prediction rules, is this variant likely to result in nonsense mediated decay? Answer yes or no." }
No
At the end of the last exon, after the main domain
[ "Other" ]
[]
null
AITX-00016
{ "clinical_context": "Malignant Peripheral Nerve Sheath Tumor and Pheochromocytoma", "genotype": [ { "gene": "NF1", "transcript": "NM_001042492.3", "variant_cdna": "c.3728T>C", "variant_protein": "p.(Leu1243Pro)", "zygosity": "heterozygous" } ] }
{ "answer_format": "multiple_choice", "category": "Variant_Assessment", "date_submitted": "2025-08-01", "prompt": "In which functional domain does this variant occur? Answer choices: CSRD, TBD, GRD, Sec14-PH, HLR, NLS, SBR." }
GRD
GRD, GAP related domain (1198โ€“1549 residues)
[ "PubMed/Literature" ]
[ "https://www.mdpi.com/2073-4425/13/7/1130#" ]
null
README.md exists but content is empty.
Downloads last month
86

Space using aitxchallenge/Phase1_Model_Validator 1